

Bradford S Hoppe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3502657/publications.pdf>

Version: 2024-02-01

170
papers

3,795
citations

117625
34
h-index

155660
55
g-index

171
all docs

171
docs citations

171
times ranked

3580
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of Lymphoma and Other Hematologic Malignancies Training Needs Among Radiation Oncology Residents: a Brief Report. <i>Journal of Cancer Education</i> , 2023, 38, 201-205.	1.3	2
2	Comparative Effectiveness of Proton Therapy versus Photon Radiotherapy in Adolescents and Young Adults for Classical Hodgkin Lymphoma. <i>International Journal of Particle Therapy</i> , 2022, 8, 21-27.	1.8	0
3	Establishing Cost-Effective Allocation of Proton Therapy for Patients With Mediastinal Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 158-166.	0.8	7
4	Evaluating Disparities in Proton Radiation Therapy Use in AHOD1331, a Contemporary Children's Oncology Group Trial for Advanced-Stage Hodgkin Lymphoma. <i>International Journal of Particle Therapy</i> , 2022, 8, 55-57.	1.8	4
5	Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 890-900.	0.8	3
6	Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?. <i>Radiotherapy and Oncology</i> , 2022, 166, 171-179.	0.6	27
7	Chemoradiation with Hypofractionated Proton Therapy in Stage II-III Non-Small Cell Lung Cancer: A Proton Collaborative Group Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 732-741.	0.8	5
8	Carbon ion radiotherapy in the management of non-small cell lung cancer. <i>Precision Radiation Oncology</i> , 2022, 6, 69-74.	1.1	3
9	Real World Long-term Follow-up Experience with Yttrium-90Âbritumomab tiuxetan in Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 618-625.	0.4	4
10	Five- and seven-year outcomes for image-guided moderately accelerated hypofractionated proton therapy for prostate cancer. <i>Acta Oncologica</i> , 2022, 61, 468-477.	1.8	1
11	A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome. <i>Blood Advances</i> , 2022, 6, 4241-4250.	5.2	5
12	Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radiology society appropriate use criteria. <i>Leukemia and Lymphoma</i> , 2021, 62, 1057-1065.	1.3	4
13	Risk of Pneumonitis and Outcomes After Mediastinal Proton Therapy for Relapsed/Refractory Lymphoma: A PTCOG and PCG Collaboration. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 220-230.	0.8	7
14	Outcomes of Hepatosplenic T-Cell Lymphoma: The Mayo Clinic Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 106-112.e1.	0.4	9
15	A comparative study of prostate PTV margins for patients using hydrogel spacer or rectal balloon in proton therapy. <i>Physica Medica</i> , 2021, 81, 47-51.	0.7	6
16	Promising long-term results with proton therapy for localized prostate cancer. <i>Nature Reviews Urology</i> , 2021, 18, 137-138.	3.8	1
17	Second tumor risk in children treated with proton therapy. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28941.	1.5	23
18	Postoperative or Salvage Proton Radiotherapy for Prostate Cancer After Radical Prostatectomy. <i>International Journal of Particle Therapy</i> , 2021, 7, 52-64.	1.8	0

#	ARTICLE	IF	CITATIONS
19	Consensus Statement on Proton Therapy for Prostate Cancer. International Journal of Particle Therapy, 2021, 8, 1-16.	1.8	9
20	Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate-risk Hodgkin lymphoma treated with chemotherapy and radiation therapy: FDG-PET parameter analysis in a subgroup from COG AHOD0031. Pediatric Blood and Cancer, 2021, 68, e29212.	1.5	13
21	Comparable Efficacy of Reduced Dose Radiation Therapy for the Treatment of Early Stage Gastric Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue. Advances in Radiation Oncology, 2021, 6, 100714.	1.2	6
22	What men want: Results from a national survey on decision making for prostate cancer treatment and research participation. Clinical and Translational Science, 2021, 14, 2314-2326.	3.1	4
23	Pulmonary dose tolerance in hemithorax radiotherapy for Ewing sarcoma of the chest wall: Are we overestimating the risk of radiation pneumonitis?. Pediatric Blood and Cancer, 2021, 68, e29287.	1.5	1
24	Radiation Therapy Across Pediatric Hodgkin Lymphoma Research Group Protocols: A Report From the Staging, Evaluation, and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (CAYAH) Group. International Journal of Radiation Oncology Biology Physics, 2021, , .	0.8	11
25	Carbon Ion Radiotherapy in the Management of Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1169-1179.	3.7	4
26	Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria. International Journal of Radiation Oncology Biology Physics, 2021, 111, 36-44.	0.8	6
27	Radiation therapy related cardiac disease risk in childhood cancer survivors: Updated dosimetry analysis from the Childhood Cancer Survivor Study. Radiotherapy and Oncology, 2021, 163, 199-208.	0.6	17
28	Heterogeneity in Radiotherapeutic Parameter Assumptions in Cost-Effectiveness Analyses in Prostate Cancer: A Call for Uniformity. Value in Health, 2021, 25, 171-177.	0.3	0
29	Executive Summary of Clinical and Technical Guidelines for Esophageal Cancer Proton Beam Therapy From the Particle Therapy Co-Operative Group Thoracic and Gastrointestinal Subcommittees. Frontiers in Oncology, 2021, 11, 748331.	2.8	4
30	Utilization and Cost Effectiveness of First-Line Yttrium-90 Ibritumomab Tiuxetan in Low-Grade Follicular and Marginal Zone Lymphomas Compared to Standard of Care Bendamustine Plus Rituximab: A Real-World Experience. Blood, 2021, 138, 4020-4020.	1.4	0
31	The Meaningless Meaning of Mean Heart Dose in Mediastinal Lymphoma in the Modern Radiation Therapy Era. Practical Radiation Oncology, 2020, 10, e147-e154.	2.1	51
32	Follow Your Heart. International Journal of Radiation Oncology Biology Physics, 2020, 106, 17-18.	0.8	0
33	Expert consensus statements for Waldeyer's ring involvement in pediatric Hodgkin lymphoma: The staging, evaluation, and response criteria harmonization (SEARCH) for childhood, adolescent, and young adult Hodgkin lymphoma (CAYAH) group. Pediatric Blood and Cancer, 2020, 67, e28361.	1.5	7
34	Radiotherapy in Early-stage Gastric MALT. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 770-775.	1.3	4
35	Development and validation of an age-scalable cardiac model with substructures for dosimetry in late-effects studies of childhood cancer survivors. Radiotherapy and Oncology, 2020, 153, 163-171.	0.6	7
36	Image-guided hypofractionated double-scattering proton therapy in the management of centrally-located early-stage non-small cell lung cancer. Acta Oncologica, 2020, 59, 1164-1170.	1.8	6

#	ARTICLE	IF	CITATIONS
37	Long-Term Outcomes in 10-Year Survivors of Early-Stage Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2020, 107, 522-529.	0.8	2
38	Carbon Ion Radiotherapy in the Treatment of Pancreatic Cancer. Pancreas, 2020, 49, 737-743.	1.1	5
39	Patient preferences for reducing bowel adverse events following prostate radiotherapy. PLoS ONE, 2020, 15, e0235616.	2.5	2
40	Stage III nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood, 2020, 135, 2365-2374.	1.4	30
41	A positive approach: advances in proton therapy for the treatment of mediastinal lymphoma. Expert Review of Hematology, 2020, 13, 197-200.	2.2	1
42	Impact of Detecting Occult Pathologic Nodal Disease During Resection for Malignant Pleural Mesothelioma. Clinical Lung Cancer, 2020, 21, e274-e285.	2.6	2
43	Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. International Journal of Radiation Oncology Biology Physics, 2020, 107, 909-933.	0.8	67
44	Hypofractionated Proton Therapy with Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial from the University of Florida and Proton Collaborative Group. International Journal of Radiation Oncology Biology Physics, 2020, 107, 455-461.	0.8	21
45	Carbon ion radiation therapy in breast cancer: a new frontier. Breast Cancer Research and Treatment, 2020, 181, 291-296.	2.5	14
46	Irradiating Residual Disease to 30 Gy with Proton Therapy in Pediatric Mediastinal Hodgkin Lymphoma. International Journal of Particle Therapy, 2020, 6, 11-16.	1.8	4
47	Image-Guided Hypofractionated Proton Therapy in Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Study. International Journal of Particle Therapy, 2020, 7, 1-10.	1.8	6
48	Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?. International Journal of Particle Therapy, 2020, 7, 13-20.	1.8	3
49	Estimating the Number of Patients Eligible for Carbon Ion Radiotherapy in the United States. International Journal of Particle Therapy, 2020, 7, 31-41.	1.8	7
50	Principles of Radiation Therapy for Hodgkin Lymphoma. Hematologic Malignancies, 2020, , 171-197.	0.2	1
51	Comparison of Techniques for Involved-Site Radiation Therapy in Patients With Lower Mediastinal Lymphoma. Practical Radiation Oncology, 2019, 9, 426-434.	2.1	22
52	Immunotherapy with hypofractionated radiotherapy in metastatic non-small cell lung cancer: An analysis of the National Cancer Database. Radiotherapy and Oncology, 2019, 138, 75-79.	0.6	11
53	Tomayto, tomahto: prescription dose and mean heart dose in evaluating the cardiac impact of involved-field radiation therapy for Hodgkin lymphoma survivors. Acta Oncologica, 2019, 58, 1783-1785.	1.8	2
54	Does the Incidence of Treatment-Related Toxicity Plateau After Radiation Therapy: The Long-Term Impact of Integral Dose in Hodgkin's Lymphoma Survivors. Advances in Radiation Oncology, 2019, 4, 699-705.	1.2	9

#	ARTICLE	IF	CITATIONS
55	Impact of unfavorable factors on outcomes among inoperable stage II-IV Nonsmall cell lung cancer patients treated with proton therapy. <i>Acta Oncol</i> ³ <i>gica</i> , 2019, 58, 313-319.	1.8	2
56	Radiation-induced tumor immunity in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 1605-1611.	1.9	9
57	Intrafractional Displacement of Cardiac Substructures Among Patients With Mediastinal Lymphoma or Lung Cancer. <i>Advances in Radiation Oncology</i> , 2019, 4, 500-506.	1.2	11
58	Serum Testosterone 60 Months after Passive-Scatter Proton Therapy for Localized Prostate Cancer. <i>Cancer Investigation</i> , 2019, 37, 85-89.	1.3	5
59	Patient-Reported Sexual Survivorship Following High-Dose Image-Guided Proton Therapy for Prostate Cancer. <i>Radiotherapy and Oncology</i> , 2019, 134, 204-210.	0.6	5
60	Proton therapy for thymic malignancies: multi-institutional patterns-of-care and early clinical outcomes from the proton collaborative group and the university of Florida prospective registries. <i>Acta Oncol</i> ³ <i>gica</i> , 2019, 58, 1036-1040.	1.8	12
61	Association of Combined Modality Therapy vs Chemotherapy Alone With Overall Survival in Early-Stage Pediatric Hodgkin Lymphoma. <i>JAMA Oncology</i> , 2019, 5, 689.	7.1	20
62	ITV-Based Robust Optimization for VMAT Planning of Stereotactic Body Radiation Therapy of Lung Cancer. <i>Practical Radiation Oncology</i> , 2019, 9, 38-48.	2.1	16
63	Pulmonary Function after Proton Therapy for Hodgkin Lymphoma. <i>International Journal of Particle Therapy</i> , 2019, 5, 1-4.	1.8	1
64	Cardiac MRI for Detecting Early Cardiac Toxicity after Proton Therapy for Hodgkin Lymphoma. <i>International Journal of Particle Therapy</i> , 2019, 5, 41-44.	1.8	5
65	Survivor and Caregiver Expectations and Preferences Regarding Lung Cancer Treatment. <i>International Journal of Particle Therapy</i> , 2019, 6, 42-49.	1.8	4
66	Letter to the editor in response to Hopper et al, "Salvage image guided radiation therapy to the prostate after cryotherapy failure". <i>Advances in Radiation Oncology</i> , 2018, 3, 469.	1.2	0
67	Long-term outcomes following proton therapy for prostate cancer in young men with a focus on sexual health. <i>Acta Oncol</i> ³ <i>gica</i> , 2018, 57, 582-588.	1.8	17
68	Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 652-669.	0.8	71
69	Mediastinal Lymphoma. <i>Practical Guides in Radiation Oncology</i> , 2018, , 369-380.	0.1	0
70	Proton therapy in stage II-IV non-small cell lung cancer: pattern of care and impact on trial accrual. <i>Acta Oncol</i> ³ <i>gica</i> , 2018, 57, 692-693.	1.8	5
71	Rectal Culture and Sensitivity Analysis for Reducing Sepsis Risk After Fiducial Marker Placement. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1243-1245.	1.3	1
72	Improving Male Reproductive Health After Childhood, Adolescent, and Young Adult Cancer: Progress and Future Directions for Survivorship Research. <i>Journal of Clinical Oncology</i> , 2018, 36, 2160-2168.	1.6	48

#	ARTICLE	IF	CITATIONS
73	Rationale and early outcomes for the management of thymoma with proton therapy. Translational Lung Cancer Research, 2018, 7, 106-113.	2.8	15
74	Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017. Clinical Cancer Research, 2018, 24, 3500-3509.	7.0	3
75	Proton therapy for pediatric malignancies: Fact, figures and costs. A joint consensus statement from the pediatric subcommittee of PTCOG, PROS and EPTN. Radiotherapy and Oncology, 2018, 128, 44-55.	0.6	46
76	Stereotactic Ablative Body Radiotherapy for Primary Non-Small-Cell Lung Cancer: Achieving Local Control with a Lower Biologically Effective Dose. Cancer Investigation, 2018, 36, 289-295.	1.3	1
77	Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. Blood, 2018, 132, 1635-1646.	1.4	86
78	Utilization of Radiation for Pediatric Hodgkin Lymphoma. Pediatric Oncology, 2018, , 313-341.	0.5	1
79	Staging Evaluation and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent and Young Adult Hodgkin Lymphoma (CAYAH): Methodology statement. Pediatric Blood and Cancer, 2017, 64, e26421.	1.5	35
80	Pulmonary Toxicity Following Proton Therapy for Thoracic Lymphoma. International Journal of Radiation Oncology Biology Physics, 2017, 99, 494-497.	0.8	14
81	Optimal Therapy for Early-Stage Hodgkin's Lymphoma: Risk Adapting, Response Adapting, and Role of Radiotherapy. Current Oncology Reports, 2017, 19, 34.	4.0	12
82	Importance of baseline PET/CT imaging on radiation field design and relapse rates in patients with Hodgkin lymphoma. Advances in Radiation Oncology, 2017, 2, 197-203.	1.2	11
83	Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee. International Journal of Radiation Oncology Biology Physics, 2017, 99, 825-842.	0.8	66
84	Five-year outcomes from a prospective trial of image-guided accelerated hypofractionated proton therapy for prostate cancer. Acta Oncologica, 2017, 56, 963-970.	1.8	31
85	Sperm preservation and neutron contamination following proton therapy for prostate cancer study. Acta Oncologica, 2017, 56, 17-20.	1.8	6
86	Race Does Not Affect Tumor Control, Adverse Effects, or Quality of Life after Proton Therapy. International Journal of Particle Therapy, 2017, 3, 461-472.	1.8	2
87	Comparing Breath Hold and Free Breathing during Intensity-Modulated Radiation Therapy and Proton Therapy in Patients with Mediastinal Hodgkin Lymphoma. International Journal of Particle Therapy, 2017, 3, 492-496.	1.8	15
88	Evaluating Cardiac Biomarkers after Chemotherapy and Proton Therapy for Mediastinal Hodgkin Lymphoma. International Journal of Particle Therapy, 2017, 4, 35-38.	1.8	4
89	Proton Therapy for Pediatric Hodgkin Lymphoma. Pediatric Blood and Cancer, 2016, 63, 1522-1526.	1.5	20
90	A Phase 2 Trial of Concurrent Chemotherapy and Proton Therapy for Stage III Non-Small Cell Lung Cancer: Results and Reflections Following Early Closure of a Single-Institution Study. International Journal of Radiation Oncology Biology Physics, 2016, 95, 517-522.	0.8	49

#	ARTICLE	IF	CITATIONS
91	Proton therapy patterns-of-care and early outcomes for Hodgkin lymphoma: results from the Proton Collaborative Group Registry. <i>Acta Oncol</i> , 2016, 55, 1378-1380.	1.8	18
92	ACR Appropriateness Criteria® Hodgkin Lymphoma—Unfavorable Clinical Stage I and II. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 384-395.	1.3	3
93	ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 535-544.	1.3	4
94	Does Race Influence Health-related Quality of Life and Toxicity Following Proton Therapy for Prostate Cancer?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 261-265.	1.3	7
95	Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 505-516.	0.8	125
96	Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 422-434.	0.8	90
97	Proton Therapy as Salvage Treatment for Local Relapse of Prostate Cancer Following Cryosurgery or High-Intensity Focused Ultrasound. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 465-471.	0.8	9
98	Patient-Reported Quality of Life in Men with Transurethral Resection of the Prostate Undergoing Proton Therapy for Management of Prostate Cancer. <i>International Journal of Particle Therapy</i> , 2016, 2, 518-524.	1.8	4
99	Bacterial Urinary Tract Infection after Transrectal Placement of Fiducial Markers prior to Proton Radiotherapy for Prostate Cancer. <i>International Journal of Particle Therapy</i> , 2016, 3, 21-26.	1.8	4
100	Controversies in proton therapy for prostate cancer. <i>Chinese Clinical Oncology</i> , 2016, 5, 55-55.	1.2	3
101	ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma. <i>Oncology</i> , 2016, 30, 1099-103, 1106-8.	0.5	2
102	Hemorrhagic Radiation Cystitis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 331-336.	1.3	41
103	ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 610-620.	1.3	9
104	Proton therapy to the subdiaphragmatic region in the management of patients with Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2019-2024.	1.3	13
105	Re: Radiation for Prostate Cancer: Intensity Modulated Radiation Therapy versus Proton Beam. <i>Journal of Urology</i> , 2015, 194, 1507-1509.	0.4	0
106	Radiation for Prostate Cancer: Intensity Modulated Radiation Therapy versus Proton Beam. <i>Journal of Urology</i> , 2015, 193, 1089-1091.	0.4	19
107	Rectal Toxicity After Proton Therapy For Prostate Cancer: An Analysis of Outcomes of Prospective Studies Conducted at the University of Florida Proton Therapy Institute. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 172-181.	0.8	41
108	Expert Radiation Oncologist Interpretations of Involved-Site Radiation Therapy Guidelines in the Management of Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 40-45.	0.8	21

#	ARTICLE	IF	CITATIONS
109	Proton therapy in the management of non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2608-2612.	1.3	19
110	Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. <i>Cancer</i> , 2014, 120, 1076-1082.	4.1	82
111	ACR appropriateness Criteria® pediatric Hodgkin lymphoma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1305-1312.	1.5	16
112	Salvage of Locally Recurrent Prostate Cancer After Definitive Radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 411-416.	1.3	9
113	Proton Therapy in the Management of Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 387-392.	2.0	5
114	Management of Radiation Proctitis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 517-523.	1.3	18
115	ACR Appropriateness Criteria Follow-up of Hodgkin Lymphoma. <i>Journal of the American College of Radiology</i> , 2014, 11, 1026-1033.e3.	1.8	16
116	Proton therapy for Hodgkin lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 203-211.	2.3	4
117	Five-Year Outcomes from 3 Prospective Trials of Image-Guided Proton Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 596-602.	0.8	103
118	Involved-Node Proton Therapy in Combined Modality Therapy for Hodgkin Lymphoma: Results of a Phase 2 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 1053-1059.	0.8	60
119	Testosterone Replacement Therapy in Men with Prostate Cancer after Proton Therapy. <i>International Journal of Particle Therapy</i> , 2014, 1, 682-691.	1.8	1
120	Bacterial Urinary Tract Infection after Fiducial Marker Placement or Prostate Biopsy. <i>International Journal of Particle Therapy</i> , 2014, 1, 745-758.	1.8	2
121	Proton Therapy and Concomitant Capecitabine for Non-Metastatic Unresectable Pancreatic Adenocarcinoma. <i>International Journal of Particle Therapy</i> , 2014, 1, 692-701.	1.8	38
122	Advancing the Therapeutic Index in Stage III/IV Pediatric Hodgkin Lymphoma with Proton Therapy. <i>International Journal of Particle Therapy</i> , 2014, 1, 343-356.	1.8	6
123	First report of a prospective trial of proton therapy and concomitant capecitabine for patients with nonmetastatic unresectable pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15223-e15223.	1.6	0
124	Protons offer reduced bone marrow, small bowel, and urinary bladder exposure for patients receiving neoadjuvant radiotherapy for resectable rectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 3-8.	1.4	56
125	Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: Results of two prospective trials. <i>Acta Oncologica</i> , 2013, 52, 463-469.	1.8	17
126	Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity. <i>Acta Oncologica</i> , 2013, 52, 498-505.	1.8	66

#	ARTICLE	IF	CITATIONS
127	Outcomes in men with large prostates ($\geq 60 \text{ cm}^3$) treated with definitive proton therapy for prostate cancer. <i>Acta Oncologica</i> , 2013, 52, 470-476.	1.8	10
128	Proton therapy in a pediatric patient with stage III Hodgkin lymphoma. <i>Acta Oncologica</i> , 2013, 52, 592-594.	1.8	9
129	Hypofractionated passively scattered proton radiotherapy for low- and intermediate-risk prostate cancer is not associated with post-treatment testosterone suppression. <i>Acta Oncologica</i> , 2013, 52, 492-497.	1.8	13
130	Hip fractures and pain following proton therapy for management of prostate cancer. <i>Acta Oncologica</i> , 2013, 52, 486-491.	1.8	10
131	When is Elective Pelvic Lymph Node Irradiation Indicated in Definitive Radiotherapy for Localized Prostate Cancer?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 644-647.	1.3	4
132	Improving the Therapeutic Ratio by Using Proton Therapy in Patients With Stage I or II Seminoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 31-37.	1.3	18
133	Androgen Deprivation Therapy and Definitive Radiotherapy for Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 530-534.	1.3	8
134	Dosimetric rationale and early experience at UFPTI of thoracic proton therapy and chemotherapy in limited-stage small cell lung cancer. <i>Acta Oncologica</i> , 2013, 52, 506-513.	1.8	25
135	Proton-based chemoradiation for synchronous bilateral non-small cell lung cancers: A case report. <i>Thoracic Cancer</i> , 2013, 4, 198-202.	1.9	8
136	Postoperative Proton Therapy in the Management of Stage III Thymoma. <i>Journal of Thoracic Oncology</i> , 2013, 8, e38-e40.	1.1	15
137	Patient-reported quality of life in men with TURP undergoing proton therapy for prostate cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 220-220.	1.6	1
138	RE: Takatori K, Terashima K, Yoshida R, Horai A, Satake S, Ose T, Kitajima N, Kinoshita Y, Demizu Y, Fuwa N. Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer. <i>J Gastroenterol</i> . 2013; (E-pub only). <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, E33-4.	1.4	4
139	ACR Appropriateness Criteria: Localized nodal indolent lymphoma. <i>Oncology</i> , 2013, 27, 786-94.	0.5	4
140	Reduction of prostate intrafraction motion using gas-release rectal balloons. <i>Medical Physics</i> , 2012, 39, 5869-5873.	3.0	9
141	Early Outcomes From Three Prospective Trials of Image-Guided Proton Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 213-221.	0.8	95
142	Outcomes of Patients With Non-Hodgkin's Lymphoma Treated With Bexxar With or Without External-Beam Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1122-1127.	0.8	8
143	Proton Radiotherapy for Prostate Cancer Is Not Associated With Post-Treatment Testosterone Suppression. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1222-1226.	0.8	20
144	Protons Offer Reduced Normal-Tissue Exposure for Patients Receiving Postoperative Radiotherapy for Resected Pancreatic Head Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 158-163.	0.8	49

#	ARTICLE	IF	CITATIONS
145	Consolidative Involved-Node Proton Therapy for Stage IA-IIIB Mediastinal Hodgkin Lymphoma: Preliminary Dosimetric Outcomes From a Phase II Study. International Journal of Radiation Oncology Biology Physics, 2012, 83, 260-267.	0.8	72
146	Effective Dose Reduction to Cardiac Structures Using Protons Compared With 3DCRT and IMRT in Mediastinal Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2012, 84, 449-455.	0.8	126
147	Proton Therapy With Concurrent Chemotherapy for Non-“Small-Cell Lung Cancer: Technique and Early Results. Clinical Lung Cancer, 2012, 13, 352-358.	2.6	34
148	Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger. Cancer, 2012, 118, 4619-4626.	4.1	51
149	Proton therapy for lung cancer. Thoracic Cancer, 2012, 3, 109-116.	1.9	10
150	Selective nodal irradiation of regionally advanced non-“small-“cell lung cancer with proton therapy and IMRT: A dosimetric comparison. Thoracic Cancer, 2012, 3, 169-174.	1.9	4
151	Improving the therapeutic ratio in Hodgkin lymphoma through the use of proton therapy. Oncology, 2012, 26, 456-9, 462-5.	0.5	10
152	Proton Radiation Therapy Offers Reduced Normal Lung and Bone Marrow Exposure for Patients Receiving Dose-Escalated Radiation Therapy for Unresectable Stage III Non-Small-Cell Lung Cancer: A Dosimetric Study. Clinical Lung Cancer, 2011, 12, 252-257.	2.6	75
153	Protons Safely Allow Coverage of High-Risk Nodes for Patients with Regionally Advanced Non-Small-Cell Lung Cancer. Technology in Cancer Research and Treatment, 2011, 10, 317-322.	1.9	25
154	Consolidative Proton Therapy Following High-dose Chemotherapy and Autologous Stem Cell Transplant in an Adolescent with Relapsed Hodgkin Lymphoma. Journal of Adolescent and Young Adult Oncology, 2011, 1, 103-106.	1.3	3
155	Proton Therapy for Hodgkin Lymphoma. , 2011, , 197-203.		0
156	Proton therapy for prostate cancer. Oncology, 2011, 25, 644-50, 652.	0.5	9
157	Double-scattered proton-based stereotactic body radiotherapy for stage I lung cancer: A dosimetric comparison with photon-based stereotactic body radiotherapy. Radiotherapy and Oncology, 2010, 97, 425-430.	0.6	63
158	Cardiac sparing with proton therapy in consolidative radiation therapy for Hodgkin lymphoma. Leukemia and Lymphoma, 2010, 51, 1559-1562.	1.3	19
159	In Reply to Dr. Lo et al.. International Journal of Radiation Oncology Biology Physics, 2009, 74, 978.	0.8	0
160	Patterns and Incidence of Neural Invasion in Patients With Cancers of the Paranasal Sinuses. JAMA Otolaryngology, 2009, 135, 173.	1.2	85
161	Postoperative intensity-“modulated radiation therapy for cancers of the paranasal sinuses, nasal cavity, and lacrimal glands: Technique, early outcomes, and toxicity. Head and Neck, 2008, 30, 925-932.	2.0	46
162	Acute Skin Toxicity Following Stereotactic Body Radiation Therapy for Stage I Non-“Small-Cell Lung Cancer: Who's at Risk?. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1283-1286.	0.8	169

#	ARTICLE	IF	CITATIONS
163	Outcomes and Prognostic Variables in Adenoid Cystic Carcinoma of the Head and Neck: A Recent Experience. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1365-1372.	0.8	122
164	Unresectable Carcinoma of the Paranasal Sinuses: Outcomes and Toxicities. International Journal of Radiation Oncology Biology Physics, 2008, 72, 763-769.	0.8	82
165	Involved-Field Radiotherapy Before High-Dose Therapy and Autologous Stem-Cell Rescue in Diffuse Large-Cell Lymphoma: Long-Term Disease Control and Toxicity. Journal of Clinical Oncology, 2008, 26, 1858-1864.	1.6	50
166	Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting—the MSKCC experience. International Journal of Radiation Oncology Biology Physics, 2007, 67, 691-702.	0.8	213
167	Relapsed and Primary Refractory Diffuse Large B-Cell Lymphoma: Improving Outcome by Incorporating Involved Field Radiotherapy into a Comprehensive Second-Line High-Dose Therapy Strategy.. Blood, 2007, 110, 1893-1893.	1.4	0
168	Impaired T Helper 2 Response to Aeroallergen in Helminth-Infected Patients with Asthma. Journal of Infectious Diseases, 2004, 190, 1797-1803.	4.0	106
169	Complementation of the Radiosensitive M059J Cell Line. Radiation Research, 2000, 153, 125-130.	1.5	57
170	Targeted Radiotherapy for Early-Stage Low-Risk Pediatric Hodgkin Lymphoma Slow Early Responders: A COG AHOD0431 Analysis. Blood, 0, , .	1.4	4